FLSW - ETF AI Analysis

Top Page

Franklin FTSE Switzerland ETF (FLSW)

Rating:69Neutral

Price Target:―

FLSW, the Franklin FTSE Switzerland ETF, has a solid overall rating driven mainly by large positions in high‑quality Swiss companies like Novartis, Nestlé, and Roche, which show strong financial performance, healthy cash flows, and generally positive long‑term prospects. The fund also benefits from holdings such as ABB, Richemont, Zurich Insurance, and Swiss Re, which add stability and growth potential, though some names face valuation concerns, mixed technical signals, or slower revenue and cash flow growth. The main risk is that the ETF is concentrated in a single country and a few big sectors, so weakness in the Swiss market or those industries could weigh on performance.

Positive Factors

Low Expense Ratio

The ETF charges a relatively low fee, which helps investors keep more of their returns over time.

Strong Core Swiss Holdings

Several major Swiss companies in the top holdings, such as Roche and Novartis, have shown solid recent performance, supporting the fund’s overall results.

Defensive Sector Tilt

Heavy exposure to health care and consumer defensive sectors can help provide some stability during market downturns.

Negative Factors

Country Concentration in Switzerland

Most of the portfolio is invested in Swiss companies, which increases the fund’s sensitivity to economic and market conditions in Switzerland.

Top Holdings Concentration Risk

A small number of large positions make up a significant share of the fund, so weakness in these companies can have an outsized impact on performance.

Mixed Performance Among Key Stocks

Some notable holdings like Nestlé, Richemont, Zurich Insurance, and Swiss Re have shown weaker recent performance, which can drag on the ETF’s overall returns.

FLSW vs. SPDR S&P 500 ETF (SPY)

AUM68.29M

RegionEurope

Expense Ratio0.09%

Beta0.54

IssuerFranklin

Inception DateFeb 06, 2018

Dividend Yield2.03%

Asset ClassEquity

Index TrackedFTSE Switzerland RIC Capped Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume16,153

30 Day Avg. Volume9,912

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

45.76

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering52

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

FLSW Summary

The Franklin FTSE Switzerland ETF (FLSW) is a fund that lets you invest in a wide range of Swiss companies by tracking the FTSE Switzerland RIC Capped Index. It holds many types of businesses, including health care, banks, industrial firms, and consumer brands. Well-known holdings include Nestlé, Novartis, and Roche. Someone might invest in this ETF to diversify their portfolio internationally and gain exposure to Switzerland’s stable, high-quality companies in a single investment. A key risk is that the fund is heavily tied to the Swiss market and can go up or down with Swiss and global stock prices.

How much will it cost me?The Franklin FTSE Switzerland ETF (FLSW) has an expense ratio of 0.09%, meaning you’ll pay $0.90 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically involves lower costs compared to actively managed funds.

What would affect this ETF?The Franklin FTSE Switzerland ETF could benefit from Switzerland's stable economy and strong performance in sectors like healthcare and consumer defensive, which are less sensitive to economic downturns. However, challenges such as global economic slowdowns, regulatory changes in the pharmaceutical industry, or fluctuations in the financial sector could negatively impact its top holdings and overall performance.

FLSW Top 10 Holdings

FLSW is very much a Swiss story, with big health care names Roche and Novartis doing the heavy lifting as their shares keep rising and set the tone for the fund. UBS has also been climbing, giving the financial sleeve a welcome boost, while industrial player ABB is quietly adding steady support. On the flip side, consumer giant Nestlé has been losing steam, and insurers like Zurich and Swiss Re have been lagging, acting as a brake. Overall, it’s a concentrated bet on Swiss health care and financials within a single-country portfolio.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ROG	Roche Holding AG	13.45%	$9.12M	CHF283.12B	42.92%	73 Outperform
NOVN	Novartis AG	12.28%	$8.33M	CHF223.13B	22.27%	80 Outperform
NESN	Nestlé SA	10.56%	$7.16M	CHF190.98B	13.70%	71 Outperform
UBS	UBS Group AG	6.85%	$4.64M	$149.54B	47.08%	73 Outperform
ABB	ABB Ltd	6.34%	$4.29M	kr1.41T	36.28%	78 Outperform
ZURN	Zurich Insurance Group	3.98%	$2.70M	CHF79.42B	17.51%	78 Outperform
CFR	Compagnie Financiere Richemont SA	3.93%	$2.67M	CHF89.98B	-14.38%	78 Outperform
HOLN	Holcim	2.98%	$2.02M	CHF43.64B	-9.50%	73 Outperform
LONN	Lonza Group Ltd	2.68%	$1.81M	CHF36.19B	-13.89%	71 Outperform
SREN	Swiss Re AG	2.65%	$1.80M	CHF33.73B	2.76%	73 Outperform

FLSW Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

41.30

Positive

100DMA

40.07

Positive

200DMA

38.74

Positive

Market Momentum

MACD

0.49

Negative

RSI

61.78

Neutral

STOCH

78.31

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FLSW, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 42.24, equal to the 50-day MA of 41.30, and equal to the 200-day MA of 38.74, indicating a bullish trend. The MACD of 0.49 indicates Negative momentum. The RSI at 61.78 is Neutral, neither overbought nor oversold. The STOCH value of 78.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLSW.

FLSW Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
FLSW	―	―	$68.29M	0.09%	―
EWL	―	―	$1.67B	0.50%	―
FKU	―	―	$94.18M	0.80%	―
FGM	―	―	$90.93M	0.80%	―
EUDG	―	―	$74.47M	0.58%	―
FSZ	―	―	$45.66M	0.80%	―

Performance Comparison

FLSW

Franklin FTSE Switzerland ETF

43.21

9.21

27.09%

EWL

iShares MSCI Switzerland ETF

―

FKU

First Trust United Kingdom AlphaDEX Fund

―

FGM

First Trust Germany AlphaDEX Fund

―

EUDG

WisdomTree Europe Quality Dividend Growth Fund

―

FSZ

First Trust Switzerland AlphaDEX Fund

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents